Jazz Pharmaceuticals, Inc. (JAZZ)
Jazz Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for conditions such as narcolepsy, epilepsy, and cancer. Founded in 2003, it specializes in neuroscience and oncology, aiming to improve patients' quality of life through specialized therapies.
Company News
Ligand Pharmaceuticals executives will participate in two upcoming investor conferences: Citi 20th Annual BioPharma Conference in Boston and H.C. Wainwright 27th Annual Global Investment Conference in New York, presenting and hosting investor meetings.
Air Canada suspended its plan to resume limited flights after the Canadian Union of Public Employees (CUPE) directed flight attendants to defy a Canadian Industrial Relations Board directive to return to work. Approximately 240 flights were cancelled, with the airline planning to resume operations the following evening.
Billionaire Seth Klarman's Baupost Group significantly reduced its stake in Alphabet (Google's parent company) while increasing its position in Jazz Pharmaceuticals, a historically cheap and under-the-radar drugmaker.
UBS revised its price target for Jazz Pharmaceuticals to $113 from $117, citing challenges within the company's Sleep franchise and the failure of its Essential Tremor treatment in a clinical trial.
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
